Adelaide, South Australia, Australia
Trajan Scientific and Medical (Trajan) has appointed Marco Baccanti as CEO of its joint venture (JV) in nutritional testing, Trajan Nutrition. Mr. Baccanti’s appointment strengthens Trajan Nutrition to accelerate the growth and impact of the work and research led by Trajan and professors Maria Makrides and Robert Gibson.
Mr. Stephen Tomisich (CEO Trajan) said, “We are incredibly fortunate to have someone of Marco’s experience and seniority join the Trajan team.”
After his previous appointments in leadership positions in the science industry and research institutions in Italy, and in the government of the UAE, Mr. Baccanti was most recently the Chief Executive at Health Industries, Government of South Australia, where he was responsible for economic development in the life sciences sector. During his 4-year tenure, his organization achieved the establishment of 23 companies with over 600 new direct jobs, clinical research investments from 10 overseas biotech companies and numerous university-industry collaborations.
“Mr. Baccanti’s background and connection to the healthcare sector in Australia is ideal to accelerate our progress with Trajan Nutrition, and more broadly, adoption of Trajan’s microsampling technologies.” said Mr. Tomisich.
Mr. Tomisich highlights, “Beyond the role in leading Trajan Nutrition we see Marco as potentially leading further collaboration between Trajan, state and federal governments, universities and the healthcare sector in Australia.”
Trajan continues to drive disruption in the healthcare sector worldwide; promoting decentralization of healthcare by developing and bringing to market microsampling technologies.
Mr. Baccanti comments, “I feel very enthusiastic to join an industrial group that is experiencing such a fast, global expansion, with a clear vision to contribute and serve the evolution of global healthcare towards a more sustainable, patient-centric and delocalized approach, with a stronger focus on prevention and wellness.”
“I am totally aligned to this vision, that has been a leitmotiv in all my previous roles, in Europe, the Middle East and in Australia, and I see now this new mandate as an ideal continuation of what I have been learning and doing in my last 25 years in industry, governments and research institutions.” said Mr Baccanti.
Trajan enriches the wellbeing of a growing number of communities through improved scientific and medical tools and technologies. They have completed 7 acquisitions over 6 years, increased their workforce to over 450 staff and continue to develop partnerships with unique collaboration models with academia, industry experts and likeminded organizations.
Photo(L-R): Trajan Scientific and Medical CEO Stephen Tomisich, and Trajan Nutrition CEO Marco Baccanti.
Press release [PDF]
Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1908 568 844
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.